Metabotropic GABA receptors facilitate L-type and inhibit N-type calcium channels in single salamander retinal neurons.
1. Whole-cell voltage clamp experiments were performed on isolated spiking retinal neurons from the salamander retina. Calcium channel currents were studied using barium as the charge carrier while potassium and sodium currents were suppressed with TEA and TTX, respectively. 2. Baclofen, a metabotropic GABA receptor agonist, both enhanced and suppressed high-voltage-activated calcium channel current. Baclofen facilitated an L-type channel current, and this effect was not voltage dependent. As reported previously, baclofen inhibited an N-type channel current and this action was voltage dependent. 3. While the suppressive effect was mediated by a fast-acting, direct G-protein action, the facilitatory effect was slower and was blocked by inhibitors of protein kinase C (PKC), either GF-109203x or the PKC (19-36) sequence fragment. 4. The pharmacology of the inhibitory and facilitatory responses differed. Commonly used antagonists of metabotropic GABA receptors, CGP35348 and CGP55845, were more potent antagonists of the inhibitory response. Similarly, a selective agonist at the metabotropic GABA receptor, APMPA, was also more effective in eliciting the inhibitory response. 5. These observations indicate that there may be two baclofen-sensitive metabotropic GABA receptors with opposing effects on calcium channel current. This is the first description of a facilitatory action of GABAB receptors and indicates that GABA may not function exclusively as an inhibitory transmitter.
Shen
W
W
Departments of Physiology and Biophysics, and Ophthalmology, School of Medicine, State University of New York, Buffalo, NY 14214, USA. wenshen@acsu.buffalo.edu
Slaughter
M M
MM
D000557:Ambystoma; D000818:Animals; D001418:Baclofen / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology*; D020746:Calcium Channels, L-Type; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018755:GABA Agonists / Q000494:pharmacology*; D018756:GABA Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology; D008301:Maleimides / Q000494:pharmacology; D009474:Neurons / Q000502:physiology*; D010446:Peptide Fragments / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D018080:Receptors, GABA-B / Q000187:drug effects; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects / Q000502:physiology*; D012160:Retina / Q000166:cytology / Q000502:physiology*; D015290:Second Messenger Systems / Q000502:physiology; D013757:Tetraethylammonium Compounds / Q000494:pharmacology; D013779:Tetrodotoxin / Q000494:pharmacology
D002121:Calcium Channel Blockers; D015220:Calcium Channels; D020746:Calcium Channels, L-Type; D004791:Enzyme Inhibitors; D018755:GABA Agonists; D018756:GABA Antagonists; D007211:Indoles; D008301:Maleimides; D010446:Peptide Fragments; D018080:Receptors, GABA-B; D018094:Receptors, Metabotropic Glutamate; D013757:Tetraethylammonium Compounds; D013779:Tetrodotoxin; D011493:Protein Kinase C; D001418:Baclofen; C070515:bisindolylmaleimide I